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Conclusions: Carboplatin and vinorelbine administered i.v. and orally 
induce fewer responses than previously reported with cisplatin plus i.v. 
vinorelbine, though with overlapping 95% conﬁdence intervals. The 
current patient population had a high frequency of adverse prognostic 
variables such as poor performance status, stage 4 disease, non-epithe-
lial subtype and advanced age, reﬂecting the population of MPM usu-
ally seen in the community but considerably worse than those usually 
included in recently published trials of doublet chemotherapy. As such, 
it is noteworthy that the median survival is in excess of 9 months (me-
dian not yet reached).The regimen was easy to administer and generally 
well tolerated without any toxic deaths in spite of the poor prognostic 
patient population. Quality of life data is being analysed and should be 
compared to that of other regimens. 
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Background: Malignant mesotheliomas is increasing in Japan and 
other countries. However, the accurate pathological diagnosis of pleural 
or peritoneal mesothelioma is sometimes difﬁcult if adequate histologi-
cal and immunohistochemical analyses are undertaken. The aim of this 
study is to clarify the useful antibodies panel for distinguishing perito-
neal epithelioid mesothelioma (PEM) from ovarian carcinomas (serous 
papillary adenocarcinoma (SC) and clear cell adenocarcinomas (CC) 
Materials and Methods: Twenty-three peritoneal mesotheliomas, 16 
clear cell adenocarciomas and 20 serous papillary adenocarcinomas 
were obtained from our surgical pathology ﬁles. The immunohisto-
chemistry was undertaken using commercially available antibodies. 
The immunohistochemical scoring is semi-quantiﬁed as follows, 0, 
none or trace, 1, less than 5% tumor cells are positive, 2, 5-50% tumor 
cells are positive, and 3, more than 51% tumor cells are positive.
Results and Discussion: The positivity for each antibody in PEM, 
CC, and SC were as follows; 1) calretinin (PEM; CC; SC, 100%; 31%; 
40%), 2) WT1 (89%, 19%, 90% ), 3) thrombomodulin (94%, 38%, 
5%), 4) CK5/6 (89%, 44%, 80%), 5) D2-40 (94%, 31%, 45%), 6) CEA 
(0%, 50%, 35%), 7) CA19-9 (17%, 91%, 80%), 8) BerEP4 (0%, 94%, 
100%), 9) MOC31 (6%, 100%, 90%), 11) Napsin A (0%, 75%, 5%), 
12) ER (0%, 31%, 80%) 13) CD15 (0%, 94%, 60%). 
The degree of positive intensity of calretinin, D2-40, thrombomodulin 
in PEM was signiﬁcantly higher, and CEA, CA19-9, MOC31, BerEP4, 
CD15 and ER was signiﬁcantly lower than those in SC or CC. 
These results suggested that the combinations of positive markers (cal-
retinin, thrombomodulin, and D2-40) and negative markers (BerEP4, 
MOC31, CD15 and ER) is useful for differential diagnosis for these 
tumors. WT1 reported as “positive marker” is not able to use for dif-
ferential diagnosis between PEM and SC.
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Primary malignant lymphoreticular diseases of the lung form nearly 
0.5% primary lung tumours. In this group there is primary non-Hodg-
kin lymphoma of the lung, which is so rare to constitute 0.34% of all 
non-Hodgkin lymphomas. Choice of therapy in localised lesions is the 
resection. In this study it was aimed to deﬁne this rare disease.
In radiological examination of a 40 year-old male patient with effort-
induced dyspnea complaint had inﬁltrative appearance in upper lobe 
of right lung. This patient was found negative in regard of tuberculosis 
investigation and there was not any response to non-speciﬁc antibiotic 
therapy. At least, it was diagnosed primary lymphoma of the lung by 
transthoracic thin needle biopsy. Any pathology could not be deter-
mined during research of other systems.
In the patient to whom right posterolateral thoracotomy was performed, 
it was seen that tumours of upper lobe had been invaded into the 
middle lobe and so upper bilobectomy was done. There was not any 
complication in the postoperative period of this patient whose pathol-
ogy reporting “right upper and middle lobe MALT type marginal zone 
lymphoma”. According to Modiﬁed Ann Arbor Staging System it was 
determined as Stage IE and this patient was taken into follow-up pro-
gramme in our clinical.
We believe that in the differential diagnosis of nodular or inﬁltrative 
lesions of the lung not responding to medical therapy, we should take 
primary lung lymphoma into consideration and in localised lesions 
surgical therapy should be applied. 
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Malignant mesothelioma is a highly aggressive kind of tumor with a 
poor prognosis and a limited response to chemotherapy. Pemetrexed 
disodium (Alimta), which is a multi-targeted antimetabolite inhibiting 
the folate pathway, has demonstrated promising clinical activity in a 
wide variety of solid tumors including mesothelioma.
An 81-year old female patient was admitted to our hospital with cough 
and dyspnea. A massive unilateral pleural effusion and multiple pleural 
nodules were determined by a thorax computed tomography (TCT). 
She had the diagnosis of mesothelioma after an open lung biopsy. The 
patient had recieved radiotherapy for her primary tumor ﬁrstly. After-
wards, she had been observed for eighteen months without any symp-
toms since she had a new complaint of effort dyspnea. In the new TCT, 
there were multiple pleural nodules, massive pleural effusion in right 
hemithorax, mediastinal lymph nodes with pathological sizes and an 
underskin mass localized at the previous biopsy region; which had been 
interpreted as progression of primary tumor. It was decided to give 
chemotherapy containing pemetrexed (Alimta) 500 mg/m2 and cisplatin 
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80 mg/ m2. Following chemotherapy, the patient was evaluated with a 
TCT which showed that her underskin mass had been disappeared, her 
mediastinal lymph nodes and pleural nodules had been regressed over 
50 %; also her complaints ended after chemotherapy. 
As it is known, in the treatment of malign mesothelioma, except the 
surgery in early stage patients, the studies about the chemotherapy are 
not so hopeful. This case is presented to show that pemetrexed (Alimta) 
can be an effective chemotherapy agent in mesothelioma treatment. 
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Background: Malignant mesothelioma is an extraordinarily chal-
lenging disease to treat; however, locoregional virotherapy may be 
applicable for this aggressive disease because of the accessibility by 
intrapleural and/or intratumoral virus delivery. We previously reported 
that an attenuated adenovirus OBP-301 (Telomelysin), in which the hu-
man telomerase reverse transcriptase (hTERT) promoter element drives 
expression of E1A and E1B genes linked with an internal ribosome 
entry site, could replicate in and causes selective lysis of human cancer 
cells. In the present study, we examined the antitumor effect of Telome-
lysin on human malignant mesothelioma cell lines in vitro and in vivo. 
Results: The XTT assay demonstrated that Telomelysin could ef-
ﬁciently kill four human mesothelioma cell lines H2052, H2452, H28, 
and 211H, all of which expressed the coxsackievirus and adenovirus 
receptor (CAR), in a dose-dependent manner. In vivo antitumor ef-
fect was also evaluated in an orthotopic pleural dissemination model. 
Intrathoracic administration of 2 x 108 plaque forming units (PFU) of 
Telomelysin markedly reduced the size (1 ± 1.8 mg vs. 190 ± 75 mg, p 
< 0.01) of H2452 tumors intrathoracically implanted into BALB/c-nu/
nu mice compared to mock-treated mice. 
Conclusions: These results suggest that locoregional administra-
tion of Telomelysin into the thoracic cavity may be efﬁcacious in the 
prevention and treatment of pleural dissemination of human malignant 
mesothelioma.
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Background: Although the association between asbestos exposure and 
the development of malignant pleural mesothelioma (MPM) is well 
recognized, the relationship between asbestos contents by ﬁber type 
and the risk of development for MPM remains unclear. In this study, 
we evaluated the asbestos contents by ﬁber type in the lung and the 
primary tumor of patients with resected MPM.
Methods: Asbestos ﬁber contents in the pulmonary parenchyma and 
tumor tissues were analyzed in 3 patients with MPM by transmission 
electron microscopy with energy-dispersive X-ray analysis using a 
low-temperature ashing procedure. The geometric mean content of total 
asbestos in the control subjects without history of asbestos exposure 
were used as reference, which was 1.83 x 106 ﬁbers / g dry lung. (Ref-
erence: Sakai K et al. Asbestos Concentration and Fiber Size in Lungs 
of the Urban Residents. Japanese Journal of Public Health, 1991; 38: 
762-770)
Results: Three patients were analyzed in this study, which were 
Case1: 50-year-old man, biphasic type, pT3N2M0 in the International 
Mesothelioma Interest Group staging system, Csae2: 54-year-old 
man, biphasic type, pT2N0M0 and Case 3: 56-year-old man, epithelial 
type, pT4N0M0. All patients had a history of asbestos exposure and 
underwent an extrapleural pneumonectomy with curative intent. As-
bestos ﬁbers were not detected in the tumor tissues in all patients. The 
geometric mean content of total asbestos in lung tissues were 1.8 ± 1.4 
(x 106 ﬁbers / g dry lung), 54.2 ± 33.1 and 6.5 ± 3.7 in the case1, case2 
and case3, respectively, which showed 1 time, 29.6 times and 3.6 times 
compared with that of the control subjects. The distributions of asbestos 
by ﬁber type in each patient were very different as following. 
 chrysotile crocidolite amosite others
Case1 71% 7% 7% 15%
Case2 49% 42% 7% 2%
Case3 11% 52% 7% 30%
Conclusions: Case1 had MPM without high level exposure of asbestos. 
On the other hand, case2 and case3 showed higher concentration of 
asbestos ﬁber in the lung tissue than control subject, which evidenced 
the high level exposure of asbestos. Those two patients also had a large 
proportion of crocidolite in the total asbestos ﬁbers, which might be 
associated with the development of MPM. To elucidate the relation be-
tween the pulmonary asbestos ﬁber contents by ﬁber type and develop-
ment of MPM, further investigation is considered necessary.
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Lungs represent one of the most common sites of secondary deposits of 
various primary tumors. However,incidence of endoluminal metastases 
is low(2-28%)because ﬁberoptic bronchoscopy is not performed rou-
tinely in all patients(pts) with pulmonary metastases.Also,these patients 
may also have low performance status and diagnosis is provided by 
other procedures.
During 2005 in our department 3724 bronchoscopies were done,mostly 
under suspicion on lung cancer.In 46(1.23%)endobronchial metastases 
were found.
